{"id":"https://openalex.org/W4416844752","doi":"https://doi.org/10.1158/1078-0432.30750610","title":"Supplementary Figure S4 from A First-in-Class mAb (BI-1607) Targeting Fc\u03b3RIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors","display_name":"Supplementary Figure S4 from A First-in-Class mAb (BI-1607) Targeting Fc\u03b3RIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors","publication_year":2025,"publication_date":"2025-12-01","ids":{"openalex":"https://openalex.org/W4416844752","doi":"https://doi.org/10.1158/1078-0432.30750610"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.30750610","doi":"https://doi.org/10.1158/1078-0432.30750610","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30750610","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750610/1/files/59994322.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750610/1/files/59994322.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051629490","display_name":"Javier Cort\u00e9s","orcid":"https://orcid.org/0000-0001-7623-1583","observed_orcids":["https://orcid.org/0000-0001-7623-1583"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Javier Cort\u00e9s","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7623-1583","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091608801","display_name":"Araceli Priego","orcid":"https://orcid.org/0009-0003-3441-1609","observed_orcids":["https://orcid.org/0009-0003-3441-1609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Araceli Priego","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0003-3441-1609","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059711568","display_name":"Elena Garralda","orcid":"https://orcid.org/0000-0002-4412-7842","observed_orcids":["https://orcid.org/0000-0002-4412-7842"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elena Garralda","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4412-7842","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041559941","display_name":"Katerin Rojas","orcid":"https://orcid.org/0009-0003-4261-8597","observed_orcids":["https://orcid.org/0009-0003-4261-8597"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katerin Rojas","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0003-4261-8597","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085866945","display_name":"Simon Lord","orcid":"https://orcid.org/0000-0001-7946-5609","observed_orcids":["https://orcid.org/0000-0001-7946-5609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Simon R. Lord","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7946-5609","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076298207","display_name":"Thorsten Oliver Goetze","orcid":"https://orcid.org/0000-0002-8633-2748","observed_orcids":["https://orcid.org/0000-0002-8633-2748"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thorsten O. Goetze","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8633-2748","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054650117","display_name":"Sherko K\u00fcemmel","orcid":"https://orcid.org/0000-0001-9355-494X","observed_orcids":["https://orcid.org/0000-0001-9355-494X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sherko Kuemmel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9355-494X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078099654","display_name":"Simon J. Crabb","orcid":"https://orcid.org/0000-0003-3521-9064","observed_orcids":["https://orcid.org/0000-0003-3521-9064"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Simon J. Crabb","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3521-9064","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082956749","display_name":"Zinnia Patricia Parra-Guillen","orcid":"https://orcid.org/0000-0003-1503-2710","observed_orcids":["https://orcid.org/0000-0003-1503-2710"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zinnia P. Parra-Guillen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1503-2710","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007108884","display_name":"Marie Borggren","orcid":"https://orcid.org/0009-0001-0346-1676","observed_orcids":["https://orcid.org/0009-0001-0346-1676"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marie Borggren","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-0346-1676","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065612884","display_name":"Ingrid Karlsson","orcid":"https://orcid.org/0009-0006-2466-919X","observed_orcids":["https://orcid.org/0009-0006-2466-919X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ingrid Karlsson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-2466-919X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5119942444","display_name":"Danijela Lindahl","orcid":"https://orcid.org/0009-0004-4557-3483","observed_orcids":["https://orcid.org/0009-0004-4557-3483"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danijela Lindahl","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-4557-3483","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108728970","display_name":"Linda M\u00e5rtensson","orcid":"https://orcid.org/0009-0002-9518-7359","observed_orcids":["https://orcid.org/0009-0002-9518-7359"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Linda M\u00e5rtensson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-9518-7359","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045250854","display_name":"Robert J. Oldham","orcid":"https://orcid.org/0000-0002-8007-1145","observed_orcids":["https://orcid.org/0000-0002-8007-1145"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Oldham","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8007-1145","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025722647","display_name":"Anna Ropenga","orcid":"https://orcid.org/0009-0000-6934-1741","observed_orcids":["https://orcid.org/0009-0000-6934-1741"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Ropenga","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-6934-1741","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049258782","display_name":"Ingrid Teige","orcid":"https://orcid.org/0009-0007-5996-3396","observed_orcids":["https://orcid.org/0009-0007-5996-3396"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ingrid Teige","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-5996-3396","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056353703","display_name":"Johan Erik Wallin","orcid":"https://orcid.org/0000-0002-4143-0096","observed_orcids":["https://orcid.org/0000-0002-4143-0096"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johan Wallin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4143-0096","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013771543","display_name":"Bj\u00f6rn Frend\u00e9us","orcid":"https://orcid.org/0000-0003-3177-8686","observed_orcids":["https://orcid.org/0000-0003-3177-8686"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bj\u00f6rn Frendeus","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3177-8686","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5000250788","display_name":"Andr\u00e9s McAllister","orcid":"https://orcid.org/0009-0006-5510-444X","observed_orcids":["https://orcid.org/0009-0006-5510-444X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andres McAllister","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-5510-444X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8773999810218811,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8773999810218811,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.11320000141859055,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fcgammariib","display_name":"Fc\u03b3RIIB","score":0.9570000171661377},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.9330000281333923},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.753000020980835},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.7250000238418579}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6507999897003174},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5917999744415283},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4986000061035156},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.476500004529953},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32839998602867126},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.32010000944137573},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.31690001487731934},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.29580000042915344},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2827000021934509},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.28220000863075256},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28209999203681946},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2809000015258789},{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.2646999955177307},{"id":"https://openalex.org/C2778117688","wikidata":"https://www.wikidata.org/wiki/Q264024","display_name":"Animal model","level":2,"score":0.26010000705718994}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.30750610","doi":"https://doi.org/10.1158/1078-0432.30750610","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30750610","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750610/1/files/59994322.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30750610","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750610","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.30750610","doi":"https://doi.org/10.1158/1078-0432.30750610","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30750610","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750610/1/files/59994322.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4416844752.pdf","grobid_xml":"https://content.openalex.org/works/W4416844752.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4415045955","https://openalex.org/W4416848322","https://openalex.org/W4396598551","https://openalex.org/W4308378244","https://openalex.org/W4393073096","https://openalex.org/W2099350409","https://openalex.org/W4413439116","https://openalex.org/W7207639344","https://openalex.org/W4282941780","https://openalex.org/W7166010583"],"abstract_inverted_index":{"Figure":[0],"S4.":[1],"Pharmacokinetic":[2],"(PK)":[3],"and":[4],"receptor":[5],"occupancy":[6],"(RO)":[7],"modeling":[8],"results":[9]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2025-12-01T00:00:00"}